European annals of allergy and clinical immunology最新文献

{"title":"Local allergic rhinitis in children: identification and characterization in a specialty outpatient clinic.","authors":"F Y Matsumoto, T R Tranquillini Gonçalves, D Solé, G F Wandalsen","doi":"10.23822/EurAnnACI.1764-1489.327","DOIUrl":"10.23822/EurAnnACI.1764-1489.327","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Local Allergic Rhinitis (LAR) is a phenotype defined by rhinitis symptoms with negative responses to systemic sensitization tests but with an exclusively nasal allergic inflammatory response. Data on the pediatric age group is scarce, and no Latin American data has been published so far. <b>Methods.</b> Nasal Allergen Challenge (NAC) was performed with Dermatophagoides pteronyssinus and Blomia tropicalis in six- to 18-year-old patients diagnosed with rhinitis and no systemic sensitization. NAC was monitored using subjective parameters and acoustic rhinometry. The study aimed to identify LAR in child and adolescent subjects previously diagnosed with non-allergic rhinitis (NAR) in a Brazilian specialty outpatient clinic (Allergy and Immunology). <b>Results.</b> During the study period, we analyzed 758 skin prick tests (SPT). Of those, 517 (68.2%) were diagnosed with rhinitis. Among those, 18.4% (95/517) had a negative SPT, meeting the criteria for inclusion in the study. Twenty-five patients underwent NAC, and 40% (10/25) of them, previously considered to have NAR, had a positive test and were reclassified as having LAR. Based on the analyzed characteristics, clinically differentiating LAR from NAR was impossible. <b>Conclusions.</b> This study represents the first investigation of LAR in child and adolescent subjects in Latin America, contributing significantly to the understanding of its prevalence and characteristics in this geographic area. Among a subgroup of patients lacking systemic sensitization submitted to NAC, 40% (10/25) demonstrated a positive NAC with Dermatophagoides pteronyssinus and Blomia tropicalis, warranting their reclassification to LAR. NAC with multiple allergens has been proven safe and viable in pediatric populations, affirming its critical role in the accurate diagnosis of LAR.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related Quality of Life in Hymenoptera Venom Allergy: Validation of the Italian version of the Vespid Allergy Quality of Life Questionnaire (VQLQ-i).","authors":"M Mauro, D Bignardi, I Baiardini, P Bonadonna, M C Braschi, F Emiliani, L Guerra, S Liberati, F Olivieri, V Pravettoni, D Preziosi, E Ridolo, F Rivolta, M Martini, M B Bilò","doi":"10.23822/EurAnnACI.1764-1489.325","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.325","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstructive Sleep Apnea: a risk for uncontrolled and more severe asthma in adults that we should keep an eye on.","authors":"G Martins Dos Santos, P Simão Coelho, J Gaspar Marques, S Serranho, S Santos, A Brito, P Carreiro Martins, P Leiria Pinto","doi":"10.23822/EurAnnACI.1764-1489.324","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.324","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Asthma control can be influenced by several factors, including obstructive sleep apnea (OSA). The literature reports variable prevalence and magnitude of OSA impact on asthma outcomes. The aim of our study is to analyze the frequency of high-risk for OSA in asthma patients and its impact on disease severity and control. <b>Methods.</b> We conducted a cross-sectional study at an Allergy Department with adult asthma patients recruited while undergoing routine lung function tests. Data on sex, age, body mass index, allergen sensitization, smoking habits, risk of OSA (using the Berlin questionnaire), rhinitis control (through CARAT), asthma severity (based on GINA 2023), asthma control (using the ACT), adherence to asthma treatment (through Treatment Adherence Measure) and pulmonary function test results were collected. <b>Results.</b> We included 216 patients, predominantly women (70.4%), with a median (P25-P75) age of 29.0 (21.0-45.0) years, of whom 28.2% were on GINA treatment levels 4-5. In 75.5% of cases asthma was controlled. High-risk for OSA was identified in 21.8% of patients. Asthma patients with high-risk for OSA were more likely to have uncontrolled [(47.8%; n = 22) <i>vs</i> (15.8%; n = 26); p less than 0.001] and more severe disease [(44.7%; n = 21) <i>vs</i> (23.7%; n = 40), p = 0.006]. In multivariable analysis, high-risk for OSA (OR 2.81 [95%CI 1.1.28-6.17], p = 0.010), sex (women) (OR 5.21 [95% CI 1.70-15.96], p = 0.004), uncontrolled rhinitis (OR 3.65 [95%CI 1.38-9.64], p = 0.009) and GINA asthma treatment steps 4-5 (OR 2.46 [95%CI 1.15-5.26], p = 0.020) were associated with uncontrolled asthma. <b>Conclusions.</b> It is crucial to actively investigate OSA, especially in patients with uncontrolled and more severe forms of asthma.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?","authors":"E T Korkmaz, O Aydın, D Mungan, B A Sin, Y S Demirel, S Bavbek","doi":"10.23822/EurAnnACI.1764-1489.261","DOIUrl":"10.23822/EurAnnACI.1764-1489.261","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Allergic bronchopulmonary aspergillosis (ABPA) is an endotype of severe asthma which frequently needs biologics for their steroid sparing effect. We aimed to evaluate the outcomes of reducing the omalizumab dose in patients with ABPA who were on long-term omalizumab treatment. <b>Methods.</b> Once asthma was controlled, two approaches were used to reduce total monthly omalizumab dose: 1) both extending dose intervals from 2 to 4 weeks and decrease omalizumab dose, 2) to reduce omalizumab dose while keeping dose intervals stable. <b>Results.</b> Thirteen patients with ABPA (8F/5M, mean age 53.4 ± 13.0 years) were included. Pre-omalizumab, mean numbers of attacks and hospitalizations were 2.5 ± 1.5 and 1.3 ± 0.8, mean oral corticosteroid (OCS, as methylprednisolone) dose was 12.2 ± 10.4 mg daily. First omalizumab dose reduction was made to all patients at a median time of 35 months (min 13, max 47). The 2^nd dose reduction was made in four patients at median of 23.5 months. Mean OCS decreased to 0.69 ± 0.95 mg/day (p = 0.001) in the 1st year of omalizumab, could be stopped in 11 patients in last evaluation. Attacks/hospitalizations decreased significantly to 0.31 ± 0.86 and 0, respectively, in the 1st year of omalizumab. Total omalizumab dose was reduced by median 40% (min 20, max 60) in 1st intervention and 50% (min 20, max 67) after 2nd intervention. After omalizumab dose reduction, asthma control did not deteriorate and there was no need to increase the omalizumab or OCS-dose. <b>Conclusions.</b> Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40517183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contact sensitization in pediatric patients with atopic dermatitis: a purpose for a new patch testing series for the Portuguese population.","authors":"J Costa Carvalho, I A Coutinho, C Loureiro, A C Cordeiro, L Ramos, M Gonçalo","doi":"10.23822/EurAnnACI.1764-1489.258","DOIUrl":"10.23822/EurAnnACI.1764-1489.258","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Atopic dermatitis is a prevalent condition in the pediatric population, with affected children exhibiting a susceptibility to cutaneous sensitization due to skin barrier dysfunction and immune dysregulation. Recent studies have highlighted an increased prevalence of certain allergens, which identifi-cation may be clinically relevant, with direct implications for the management of atopic dermatitis. <b>Methods.</b> We retrospective reviewed pediatric patients patch tested due to suspected contact dermatitis. Patients were divided according the diagnosis of AD, with subsequent comparison of positive results for both groups. <b>Results.</b> A total of 145 pediatric patch testing were analyzed, 44.1% (n = 63) with the diagnosis of atopic dermatitis. There were notable differences in sensitization rates of relevant allergens between groups and when compared to other European studies. Based on the most prevalent and relevant allergens, we proposed an adapted hapten series for assessing portuguese pediatric patients with AD and suspicion of concomitant allergic contact dermatitis. <b>Conclusions.</b> Our findings confirmed the geograph-ic sensitization variability and emphasize the need for pediatric adaptation and \"individualized baseline series\".</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45527455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with asthma exacerbations in schoolchildren: an experience in clinical practice.","authors":"G Ciprandi, M Giuliano, I Schiavetti, M Miraglia Del Giudice, M A Tosca","doi":"10.23822/EurAnnACI.1764-1489.255","DOIUrl":"10.23822/EurAnnACI.1764-1489.255","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46669301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 infection and vaccination in patients with hereditary angioedema: a multicentric study.","authors":"I C Farinha, B Tavares, N Sousa, E Almeida, C Lozoya, F S Regateiro, A Todo-Bom, E Faria","doi":"10.23822/EurAnnACI.1764-1489.295","DOIUrl":"10.23822/EurAnnACI.1764-1489.295","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Due to similarities between the pathophysiological mechanisms of hereditary angioedema (HAE) and COVID-19, it has been hypothesized that SARS-CoV-2 infection may trigger HAE attacks or, alternatively, that HAE patients may experience different of COVID-19 disease severity. Furthermore, the potential for COVID-19 vaccination to trigger angioedema attacks in patients with HAE is still not completely defined. The objective is to characterize the exacerbations and clinical manifestations associated with COVID-19 infection and describe the adverse effects of COVID-19 vaccination in patients with HAE.<b>Methods.</b> Retrospective observational, descriptive, non-interventional, multicenter study conducted in four Allergy Units and Departments in Central Portugal between March 2020 and July 2022. HAE patient data were obtained from electronic medical records. <b>Results.</b> The study included 34 patients (67.6% female): 26 with HAE type 1, 5 with HAE type 2, and 3 with HAE with normal C1 inhibitor. Most patients with HAE type 1 and 2 were receiving long-term prophylaxis. Among the 32 patients who received COVID-19 vaccination, 86 doses, were administered with one angioedema attack (1.2%) associated with vaccination. A small increase in the average number of attacks was observed in the year following COVID vaccination (7.1 <i>versus</i> 6.2 in the previous year, p = 0.029), however, this difference is unlikely to be clinically significant, as the context of the COVID-19 pandemic likely introduced numerous confounders. During the study period, 16 HAE patients had COVID-19, all presenting with mild disease. Four out of 16 patients (25%) reported angioedema attacks during COVID-19, and 43.8% during the convalescence period (3 months after infection). <b>Conclusions.</b> Patients with HAE can safely receive COVID-19 vaccination. The severity of COVID-19 infection does not appear to be increased in HAE patients.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9456818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of skin tests with polyethylene glycol and polysorbate 80 in the vaccination campaign for COVID-19: results from an Italian multicenter survey.","authors":"M C Montera, A Giordano, C Asperti, A Aruanno, C E Barzaghi, D Bignardi, P Borrelli, L Bommarito, M Busa, P Calafiore, V Carusi, M Cinquini, G Cortellini, R Cocchi, F D'Auria, F De Caro, A Demonte, E Di Leo, M Di Lizia, A Di Rienzo, F Fumagalli, P Kihlgren, F Lodi Rizzini, D Macchia, G Manzotti, A M Marra, P Mileto, S Mietta, M Montagni, E Nettis, E Nucera, S Peveri, D Pivetta, M Pirisi, G A Ramirez, F Rivolta, A Rizzi, A Savoia, A Pedicini, A Scarpa, M Zambito, G Zisa, M-R Yacoub","doi":"10.23822/EurAnnACI.1764-1489.291","DOIUrl":"10.23822/EurAnnACI.1764-1489.291","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> International guidelines suggested skin tests with Polyethylene-glycol (PEG) and polysorbate 80 (PS-80), to investigate a possible hypersensitivity to these excipients either to identify subjects at risk of developing allergic reactions to Covid-19 vaccines, or in patients with suspected IgE mediated hypersensitivity reactions (HR) to the Covid-19 vaccine. The main purpose of this study was to investigate the prevalence of PEG and PS sensitization in patients with a clinical history of HR to drugs containing PEG/PS and in patients with a suspected Covid-19 vaccine immediate HR. <b>Methods.</b> This was a multicenter retrospective study conducted by allergists belonging to 20 Italian medical centers. Skin testing was performed in 531 patients with either a clinical history of suspected hypersensitivity reaction (HR) to drugs containing PEG and/or PS-80 (group 1:362 patient) or a suspected HR to Covid-19 vaccines (group 2: 169 patient), as suggested by the AAIITO/SIAAIC guidelines for the \"management of patients at risk of allergic reactions to Covid-19 vaccines\" [1]. <b>Results.</b> 10/362 (0.02%) had positive skin test to one or both excipients in group 1, 12/169 (7.1%) in group 2 (p less than 0.01). In group 2 HRs to Covid-19 vaccines were immediate in 10/12 of cases and anaphylaxis occurred in 4/12 of patients. <b>Conclusions.</b> The positivity of skin test with PEG and or PS before vaccination is extremely rare and mostly replaceable by an accurate clinical history. Sensitization to PEG and PS has to be investigated in patients with a previous immediate HR to a Covid-19 vaccine, in particular in patients with anaphylaxis.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9180520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic esophagitis as a side-effect of allergen immunotherapy: protocol for a systematic review and meta-analysis.","authors":"C Pitsios, C M Rossi, I Terreehorst, E Heffler, M Votto, G N Konstantinou, A Alvarez-Perea, A Bakirtas, E Apostolidou, D Antolin-Amerigo, G K Nikolopoulos, O Pfaar, A Cianferoni","doi":"10.23822/EurAnnACI.1764-1489.311","DOIUrl":"10.23822/EurAnnACI.1764-1489.311","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Sensitization to food and airborne allergens is common in the majority of patients with eosinophilic esophagitis (EoE). Although there is not a direct cause-effect relationship of IgE-mediated allergy with the pathogenesis of EoE, there is a growing evidence that oral desensitization to food and sublingual immunotherapy (SLIT) may induce the development of EoE as an adverse effect. As part of the 'EoE and Allergen Immunotherapy (AIT)' Task Force funded by the European Academy of Allergy and Clinical Immunology (EAACI), a systematic approach will be followed to review the evidence from the published scientific literature on the development of EoE in children and adults under any type of AIT. <b>Methods.</b> This systematic review will be carried out following the PRISMA statement guidelines. Studies will be assessed for inclusion in the review according to the Population-Interventions-Comparators-Outcomes (PICO) criteria. <b>Results.</b> Expected outcomes will provide evidence on the AIT-EoE development connection. <b>Conclusions.</b> The findings from this review will be used as a reference to provide useful guidelines for physicians treating patients with EoE and/or are practicing AIT.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10516228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"D-dimer levels decline after immunosuppressive treatment rather than anticoagulant treatment in severe autoimmune chronic spontaneous urticaria.","authors":"D Baskurt, E Sarac, R Asero, E Kocatürk","doi":"10.23822/EurAnnACI.1764-1489.272","DOIUrl":"10.23822/EurAnnACI.1764-1489.272","url":null,"abstract":"<p><strong>Summary: </strong>Chronic spontaneous urticaria (CSU) is a common dermatological condition presenting with wheals and/or angioedema for more than 6 weeks. The role of autoimmunity and inflammation in the pathogenesis of CSU have been studied, but the precise mechanism remains unknown. Association with coagulation cascade has been suggested based on the observations of increased coagulation indicators such as serum D-dimer levels. We report an omalizumab refractory case of severe CSU with high D-Dimer levels that declined only after disease remission with cyclosporine treatment but not with anticoagulation. Activation of coagulation cascade occurs secondary to the pro-inflammatory state in CSU patients and the correlation between D-dimer levels and disease activity may indicate the need for more studies to better understand the relationship of D-dimer levels and Omalizumab resistance. Clinicians should consider this relationship in CSU patients with significant D-dimer levels before considering treatment with anticoagulants.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40455117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}